medigraphic.com
ISSN 1870-2821 (Impreso)
Organo Oficial de la Asociación Mexicana de Mastología

2016, Número 1

<< Anterior Siguiente >>

Rev Mex Mastol 2016; 6 (1)


Actualidades en radioterapia para cáncer de mama

Poitevin CA, Ramos PR, Chávez NJ

Idioma: Español
Referencias bibliográficas: 13
Paginas: 6-8
Archivo PDF: 132.44 Kb.


RESUMEN

El tratamiento estándar para cáncer de mama en etapas tempranas es cirugía conservadora y radioterapia postoperatoria. En este artículo de revisión se incluye la evidencia más actual sobre el control local y la supervivencia, el uso de dosis de incremento, la radioterapia a ganglios, el hipofraccionamiento y la asociación con terapias blanco.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)*. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet. 2011; 378: 1707-1716.

  2. Bartelink H, Philippe Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J et al, on behalf of the European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015; 16: 47-56.

  3. Strnad V, Hannoun-Levi JM, Guinot JL, Lössl K, Kauer-Dorner D, Resch A et al, on behalf of Working Group Breast Cancer of GEC-ESTRO. Recommendations from GEC ESTRO Breast Cancer Working Group (I): Target definition and target delineation for accelerated or boost partial breast irradiation using multicatheter interstitial brachytherapy after breast conserving closed cavity surgery. Radiotherapy and Oncology. 2015; 115(3): 342-348.

  4. Koulis TA, Phan T, Olivotto IA. Hypofractionated whole breast radiotherapy: current perspectives. Breast Cancer (Dove Med Press). 2015; 27(7): 363-370.

  5. Strnad V, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T et al, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomized, phase 3, non-inferiority trial. Lancet. 2016; 387(10015): 229-238.

  6. Veronesi U, Orecchia R, Maisonneuve P, Viale G, Romensz N, Sangalli C et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomized controlled equivalence trial. Lancet Oncol 2013; 14: 1269-1277

  7. Vaidya JS, Bulsara L, Wenz F, Joseph D, Saunders C, Massarut S. Pride, prejudice or science: attitudes towards the results of the TARGIT —A trial of targeted intraoperative radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys. 2015; 92(3): 491-497.

  8. Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H et al; EORTC Radiation Oncology and Breast Cancer Groups. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015; 373: 317-327.

  9. Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A et al; MA.20 Study Investigators. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015; 373 (4): 307-316.

  10. Thorsen LB, Offersen BV, Danø H, Berg M, Jensen I, Pedersen AN et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol. 2015; 34(4): 314-320.

  11. Bernier J, Rossier C, Horiot JC. Recent advances in regional treatment of breast carcinoma. Crit Rev Oncol Hematol. 2016; 99: 107-114.

  12. ESTRO breast cancer consensus guidelines. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1 q. Radiotherapy and Oncology. 2016; 118: 205-208.

  13. Pernin V, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B et al. Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer. Br J Radiol. 2015; 88(1048): 20140800.




2020     |     www.medigraphic.com